BEUDAMED
    FDA PMA FDA Class 3 30-Day Notice Accepted 🇺🇸 United States

    Hybrid Stent Graft, Thoracic Aortic Lesion Treatment

    PMA: P210006 · Supplement: S002 · Decision Jun 16, 2022
    View on FDA
    Classifications
    1
    FEI Numbers
    3
    Registration Numbers
    3

    Basic Information

    Device Name
    Hybrid Stent Graft, Thoracic Aortic Lesion Treatment
    Trade Name
    Thoraflex Hybrid
    PMA Number
    P210006
    Supplement Number
    S002
    Device Class
    FDA Class 3
    Product Code
    QSK
    Generic Name
    Hybrid stent graft, thoracic aortic lesion treatment
    Medical Specialty
    Unknown
    Advisory Committee
    Cardiovascular
    Decision
    30-Day Notice Accepted
    Decision Code
    OK30
    Decision Date
    June 16, 2022
    Date Received
    May 19, 2022
    Supplement Type
    30-Day Notice
    Supplement Reason
    Process Change - Manufacturer/Sterilizer/Packager/Supplier
    Expedited Review
    N

    Advisory Committee Statement

    Implementation of a new in-process inspection step, new equipment for aeration and new colorant resin for a component of the delivery system of the Thoraflex Hybrid device.

    Classifications

    This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

    Product Code Device Name
    QSK Hybrid Stent Graft, Thoracic Aortic Lesion Treatment